Aspirin anticancer mechanism uncovered.
Findings obtained from a trial reported in Cancer Epidemiology, Biomarkers, and Prevention reveal a previously unknown mechanism for aspirin in cancer prevention. *
Subjects received 325 mg aspirin or a placebo for 60 days. Using a technique known as metabolic profiling, levels of 363 metabolites involved in most human biochemical pathways were measured in all participants.
Cornelia Ulrich, PhD, and associates found that aspirin decreased levels of both forms of the onco-metabolite 2-hydroxyglutarate by 12% among the trial subjects and by up to 34% in colorectal cancer cell lines. (Increased levels of 2-hydroxyglutarate have been found in blood and brain cancers.) The researchers also determined that salicylate, the primary aspirin metabolite, inhibits an enzyme involved in 2-hydroxyglutarate production.
"It is really exciting that aspirin, which can work in colorectal cancer prevention, is now linked to a new pathway that has shown to be relevant for cancer formation," commented Dr. Ulrich.
Editor's Note: It has been hypothesized that aspirin's anti-inflammatory and antithrombotic effects are behind its apparent ability to protect against some cancers. "This new study suggests that aspirin is playing a key role in interrupting multiple pathways that are linked to cancer development," Dr. Ulrich stated. "Here we show both in the clinic and laboratory that a reduction in 2-hydroxyglutarate may identify a new mechanism for aspirin in cancer prevention."
* Cancer Epidemiol Biomarkers Prev. 2015 Nov 19.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||In The News|
|Article Type:||Brief article|
|Date:||Mar 1, 2016|
|Previous Article:||Testosterone improves insulin sensitivity in diabetic men.|
|Next Article:||Omega-3 fatty acids decrease risk of rheumatoid arthritis.|